Serum anti‑TSTD2 antibody as a biomarker for atherosclerosis‑induced ischemic stroke and chronic kidney disease

Abstract

autoantibodies can be used in the early diagnosis and treatment of atherosclerosis-related diseases. Using Protoarray ® screening of samples from patients with atherosclerosis, the present study identified thiosulfate sulfurtransferase-like domain-containing 2 (tStD2) as a novel atherosclerosis antigen. the serum tStD2 antibody levels were then quantified using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay. this demonstrated the levels of tStD2 antibodies (tStD2-abs) to be significantly higher in patients with acute cerebral infarction or chronic kidney disease than in healthy donors. the tStD2-ab levels were also found to be higher in males, older adults, smokers, in those who consumed alcohol regularly, and in those with hypertension. Furthermore, Spearman's rank correlation analysis revealed tStD2-ab levels to be strongly associated with measures of atherosclerosis severity, including plaque scores, intima-media thickness of the carotid artery and the cardio-ankle vascular index. thus, tStD2-abs may thus be a promising novel biomarker for atherosclerosis-related cerebral infarction and kidney disease.

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

“…Previously, we searched for antibody markers using serological identification through cDNA expression cloning (SEREX) and protein array methods. Our findings highlighted potential biomarkers for stroke including DIDO1, CPSF2, FOXJ2, DNAJC2, ALDOA, FH4, ASXL2, AP3D1, SERPINE1, and TSTD2 [11][12][13][14][15][16][17]. Likewise, we identified LRPAP1, CFL1, WDR1, and striatin 4 as potential markers for digestive tract tumors [18][19][20][21].…”

Rhodanese-Fold Containing Proteins in Humans: Not Just Key Players in Sulfur Trafficking

“…At the physiological level, the cellular functions of TSTD2 protein are still unknown. TSTD2’s gene expression or protein accumulation variations were reported for human traits or diseases resistance/susceptibility, but, to date, this information is too preliminary to propose physiological implications [ 90 , 91 , 92 ].…”

Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases

“…In terms of biomarker species, studies have reported enzyme, antigen, and, in recent years, nucleotide markers ( 1-3 ). However, there are still some reports on antibody markers, which include heat-shock 60-kD protein 1( 4 ), replication protein A2( 5 ), programmed cell death 11( 6 ), metalloproteinase 1, chromobox homolog 1, chromobox homolog 5( 7 ), DnaJ heat shock protein family (Hsp40) member C2( 8 ), adaptor-related protein complex 3 subunit delta 1( 9 ), serpin peptidase inhibitor, clade E member 1( 10 ), death-inducer obliterator 1, cleavage and polyadenylation specificity factor 2, forkhead box J2( 11 ) and thiosulfate sulfurtransferase-like domain-containing 2( 12 ) for acute ischemic stroke (AIS); ATPase, Ca ++ transporting, plasma membrane 4( 10 ), bone morphogenetic protein 1 ( 3 , 13 ), deoxyhypusine synthase ( 14 ), SH3 domain-binding protein 5( 15 ), prolyl carboxypeptidase ( 16 ), low-density lipoprotein receptor-related protein-associated protein 1( 17 ) and additional sex combs-like 2( 18 ) for atherosclerosis; nardilysin ( 19 ) for acute cardiac syndrome; and insulin ( 20 ), glutamic acid decarboxylase ( 21 ), adiponectin ( 22 ) and growth arrest and DNA-damage-inducible gene 34 ( 23 , 24 ), and proprotein convertase subtilisin/kexin type 9( 25 ) for diabetes mellitus (DM).…”